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Introduction {#s1}
============

Exposure to metals from both the natural environment and pollution may influence the development of chronic diseases, including cardiovascular disease (CVD). As ubiquitous components of the natural environment as well as of pollutants, multiple metals coexist in the ecosystem and reach the public through ambient air, drinking water, food, medications, and consumer products ([@c23]; [@c31]). Several prospective studies have evaluated associations between cardiovascular outcomes and exposures to single metals, such as arsenic ([@c2]; [@c19]; [@c43]), lead ([@c17]; [@c39]), and selenium ([@c27]; [@c49]). In a prospective case--control study nested in the Health Effects of Arsenic Longitudinal Study (HEALS) cohort of Bangladeshi adults exposed to high levels of arsenic via drinking water, researchers found positive associations between well-water arsenic and fatal and nonfatal CVD ([@c43]). The Strong Heart Study (SHS) further confirmed the association between urinary arsenic levels and incident CVD and coronary heart disease (CHD) among American Indians with low to moderate exposure levels ([@c19]). Baseline blood lead concentrations were significantly associated with CVD mortality during follow-up in a representative sample of U.S. adults \[National Health and Nutrition Examination Survey III (NHANES III Study), USA\] ([@c17]), whereas weak positive associations were reported between blood lead and CVD mortality (38 deaths) and ischemic heart disease mortality (based on 17 deaths) among men in the Normative Aging Study ([@c39]). On the other hand, a meta-analysis of prospective studies showed a significant inverse association between selenium status and CVD risk within a narrow selenium range, whereas a null effect of selenium supplementation on CVD was observed in randomized controlled trials (RCTs) ([@c49]). This finding might be due to a potential U-shaped association between selenium and CVD and differences in exposure levels among various study populations ([@c49]). Limited information about associations between exposures to other metals and CVD is available. For example, Lind et al. ([@c13]) reported an inverted U-shaped association between blood aluminum levels and the prevalence of carotid artery plaques in elderly residents of Uppsala, Sweden. Peters et al. ([@c25]) reported that cardiovascular mortality was associated with the duration of aluminum dust inhalation in underground gold miners, but no difference in CVD mortality was found between miners with any vs. no aluminum dust exposure.

In addition, although humans are exposed to many metals in daily life, few studies have examined the relationships between exposure to multiple metals and cardiovascular risk, particularly in China, where air pollution ([@c28]) and water pollution ([@c35]) are major public health concerns ([@c48]). Given that CHD remains a leading cause of death and disease both in China and globally ([@c21]; [@c42]), even a modest increase in CHD would translate into a large burden of increasing morbidity and mortality. Therefore, we applied a novel method to measure 23 plasma metals using inductively coupled plasma mass spectrometry (ICP-MS) in a cohort of Chinese adults, and estimated the associations between plasma metal levels and incident CHD.

Methods {#s2}
=======

Study Design and Participants {#s2.1}
-----------------------------

We used data from the Dongfeng-Tongji (DFTJ) cohort ([@c37]), an ongoing prospective study in Shiyan, China. Shiyan is an inland city located in central China. In comparison with other cities, there is no clear evidence suggesting special natural and anthropogenic sources of metals in this city. Dongfeng Motor Corporation (DMC) is one of the largest auto manufacturers in China. In 2008, the Retirement Office and the Social Insurance Center of DMC provided a list of all living retired employees ($n = 31,000$). They were invited to participate in the study, and 27,009 were enrolled (a response rate of 87%), completed questionnaires, underwent physical examinations, and provided blood specimens during September 2008--June 2010. Most of the employees who were invited but not enrolled (approximately 3,000 out of 3,991) had relocated to other cities and could not be reached ([@c37]). The participants were invited to a follow-up examination in 2013 with a follow-up rate of 96.2% ($n = 25,978$).

Ascertainment of CHD Cases {#s2.2}
--------------------------

Incident CHD events were defined as first occurrence of nonfatal myocardial infarction (MI), fatal CHD, stable and unstable angina, or coronary revascularization (coronary artery bypass graft or percutaneous transluminal coronary angioplasty) during follow-up, as recommended in guidelines for observational research from the American Heart Association ([@c14]). All participants were covered by the health-care service system of the Dongfeng Corporation and thus could to be tracked for morbidity and mortality records. Possible cases were initially identified through review of medical insurance documents, hospital records, and death certificates up to 31 December 2013 and were adjudicated by an expert panel of physicians. The medical records were available for all participants with diagnosed diseases and cover the entire follow-up period. CHD was diagnosed following the World Health Organization criteria using clinical symptoms, cardiac enzymes, and electrocardiograms or by coronary angiography (stenosis $\geq 50\%$ in at least one major coronary artery) ([@c1]). We included only definite or probable MIs, where definite MI was defined by diagnostic ECG or enzymes, and probable MI was defined by positive ECG findings in the presence of ischemic signs or symptoms or equivocal diagnostic enzymes ([@c14]). Fatal CHD cases were identified by death certificates with *International Classification of Diseases* (ICD) codes (ICD-9 410--414 and ICD-10 I20--I25). Stable angina was defined as angina without alteration of frequency or pattern for six weeks before hospitalization; unstable angina included angina occurring at rest and prolonged, new onset of serious angina, or deteriorating angina before hospitalization ([@c5]). Revascularization was verified through hospital records. At baseline, we excluded participants with self-reported CHD or diagnosed CHD with medical records (prevalent CHD cases, $n = 4,492$), participants with self-reported stroke ($n = 1,144$) or cancer ($n = 1,472$), and participants with abnormal results on resting ECG ($n = 315$). A total of 1,962 incident CHD cases were identified from the remaining participants during the follow-up until the end of 2013. Incident CHD cases were excluded if their diagnosis date was unknown, or if they were diagnosed $< 1\,\text{year}$ after completing their baseline survey ($n = 226$). We also excluded 48 cases with missing data for covariates (38 had missing baseline blood pressure data, and 10 had missing BMI values) and cases with insufficient plasma samples for metal measurements ($n = 67$). Consequently, a total of 1,621 incident CHD cases were included in the analysis. Each incident case was matched to one control that was randomly selected from study participants who were CVD-free at the end of follow-up, had complete covariate data and sufficient samples for metals analysis, and had at least as much follow-up time as the matched cases. Cases and controls were matched for sex and age (within five years).

Metals Correlation Study {#s2.3}
------------------------

Previous studies have measured metal concentrations in plasma ([@c49]), whole blood ([@c17]), or urine ([@c19]) as internal biomarkers to characterize exposures to different metals, and it is not clear whether plasma was an appropriate biological matrix for all metals that we examined. For example, it has been recommended that human exposure to chromium be characterized based on concentrations in both plasma and erythrocytes ([@c24]) because concentrations in plasma represent chromium (III) only, whereas chromium (VI) is present primarily in erythrocytes ([@c40]). Whole blood has been proposed as the best matrix for characterizing iron exposure, because 60--70% of total body iron is present in hemoglobin in circulating erythrocytes ([@c23]). Similarly, cadmium in blood is mainly concentrated in the blood cells, with low levels in human plasma ([@c23]). Therefore, we conducted a correlation substudy to compare the concentrations of each metal in plasma, whole blood, and urine samples. Those samples were collected from a separate population of 94 healthy volunteers living in Shiyan who were free of CVD, cancer, and diabetes, and who completed questionnaires and physical examinations that were similar to questionnaires and examinations completed by the nested case--control study population. Our intention was to use the findings of this analysis to support the use of plasma concentrations to characterize exposures, or to identify metals for which plasma concentrations might not be a reliable biomarker of exposure based on low correlations with concentrations measured in whole blood or urine.

Metals Variability Study {#s2.4}
------------------------

We also performed a separate study to evaluate the inter- and intra-individual variability of plasma metals by comparing plasma metal concentrations measured at baseline (in 2008) and at a follow-up visit (in 2013) in a separate group of 138 cohort members who were free of CVD, cancer, and diabetes at the baseline and follow-up visits.

Written informed consent was obtained from each participant, including participants in the correlation and variability studies, as well as the primary case--control study, and all parts of the study were approved by the Ethics and Human Subject Committees of Tongji Medical College.

Metals Exposure {#s2.5}
---------------

Peripheral venous EDTA blood specimens were collected after overnight fasting. The samples were centrifuged and frozen within two hours of collection, and stored at $- 80{^\circ}C$. We measured case and control specimens in random order, with laboratory personnel blinded to the case--control status. Similarly, samples from the correlation and variability studies were measured separately and in random order. Plasma concentrations of 23 metals were determined by Agilent 7700x ICP-MS with an octopole-based collision/reaction cell (Agilent Technologies), following previously reported protocols ([@c6]). In the metal correlation study, similar methods were used to measure metals in the whole blood ([@c6]) and urine ([@c9]). The urinary metals concentrations were standardized on creatinine.

For quality-control purposes, we measured metals in standard reference materials once in every 20 samples \[specifically, 1640a (Trace Elements in Natural Water from the National Institute of Standards and Technology) and certified reference materials (ClinChek^®^ human plasma controls for trace elements no. 8,883 and no. 8,884; Recipe Chemicals)\] and confirmed that values measured in the reference materials were within the recommended range for each metal. For titanium, rubidium, and tungsten, which did not have certified reference samples available, we assayed a spiked pooled plasma specimen (gathered randomly from 100 specimens). The spike recovery values of the three metals were 82.9--105.8%. Intra-assay and interassay CVs for all plasma metals were $< 10\%$ (see Table S1).

Metal concentrations that were below the limit of detection (LOD) (listed in Table S1) were imputed with a value equal to the half of the detection limit. More than half of the participants \[98.3%, 80.2%, and 54.0%, respectively (see Table S1)\] had plasma tungsten, tin, and uranium concentrations $< \text{LOD}$. Therefore, we excluded these metals from further analysis. For all other metals, fewer than 12% of the samples had values below the LOD (see Table S1).

Covariate Data {#s2.6}
--------------

Data on age, sex, education, medication use, smoking, alcohol consumption, physical activity, occupational history, and diet were collected at baseline by trained interviewers using semistructured questionnaires. Medication use was assessed by asking participants about all medications used in the previous 2 wk. Physical activity was classified as exercise for at least 20 min per week for more than half a year, based on information about activity at work and at leisure. Occupation category was measured as the most recent occupation engaged for more than 3 y before retirement. Diet was classified according to usual intakes of major food groups (meats, vegetables, fruits, beans, eggs, and dairy) in the previous 1 y using a simplified food frequency questionnaire. Participants also were asked about previous medical diagnoses and about their family history of specific diseases (limited to first-degree family members and doctor-diagnosed conditions), including CHD.

Standing height and body weight were measured by trained personnel during the baseline physical examination. In addition, each participant's resting blood pressure \[systolic (SBP) and diastolic (DBP)\] was measured one time, and average SBP and DBP values were calculated. Fasting blood was drawn for laboratory assays of blood lipids, fasting glucose, and renal function. Hypertension was defined if the measured BP values were $\geq 140\,\text{mmHg}$ for SBP or $\geq 90\,\text{mmHg}$ for DBP, or if the participant self-reported physician diagnosis or use of antihypertensive medications. Hyperlipidemia was defined if total cholesterol was $\geq 5.72\,\text{mmol}/L$, or triglycerides was $\geq 1.70\,\text{mmol}/L$, or the participant self-reported physician diagnosis or use of antihyperlipidemia medications. Diabetes was defined if the fasting glucose level was $\geq 7.0\,\text{mmol}/L$, or the participant self-reported physician diagnosis or use of antidiabetic medications (insulin or oral hypoglycemic agents). We applied the Modification of Diet in Renal Disease equation based on the Chinese patients with chronic kidney disease to calculate estimated glomerular filtration rates (eGFR) ([@c15]).

Statistical Analyses {#s2.7}
--------------------

Baseline characteristics of cases and controls were compared using *t*-tests or Mann-Whitney *U* tests for continuous variables, and chi-square tests for categorical variables.

We used Spearman's rank correlation analysis to explore correlations among the plasma metal concentrations in the case--control study population, after natural log-transformation to account for their right-skewed distributions. In addition, we used Spearman's rank correlations to evaluation correlations between concentrations of individual metals measured in plasma, whole blood, and urine for the metals correlation study. For the metals variability study, we derived Pearson correlation coefficients and intraclass correlation coefficients (ICCs) to assess consistency between concentrations measured at baseline and follow-up.

We used separate conditional logistic regression models to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for incident CHD and individual plasma metals categorized into quartiles according to their distributions among the controls. These models were limited to metals with at least 50% of plasma concentrations $> \text{LOD}$, and to metals that plasma was deemed to be a reliable biospecimen matrix based on the correlation substudy and prior information. All models were adjusted for baseline values of potential confounders that were selected *a priori*: body mass index (BMI, continuous), smoking (current, former, and never), smoking pack-years, alcohol consumption (current, former, and never), education ($\leq \text{primary}\,\text{school}$, middle school, $\geq \text{high}\,\text{school}$), physical activity (yes or no), family history of CHD (any or none), hypertension (yes or no, as defined above), hyperlipidemia (yes or no), diabetes (yes or no), and eGFR. Linear trend *p*-values were derived by modeling the median value of each metal quartile as a continuous variable in adjusted models.

After deriving trend *p*-values for each individual metal, we derived corresponding *q*-values for a False Discovery Rate (FDR) $< 0.05$ \[using software published by Pike ([@c26])\] to identify a subset of the 20 metals for simultaneous evaluation in a multiple-metal model that included the same covariates as the single-metal models. We also performed sensitivity analyses by additionally adjusting the multiple-metal models for each participant's most recent occupation (categorized into six groups), and for dietary consumption of meats, vegetables, fruits, beans, eggs, and dairy, with each food group modeled using a separate dichotomous variable based on consumption $\geq 5\,\text{times}\,\text{per}\,\text{week}$ or $< 5\,\text{times}\,\text{per}\,\text{week}$.

The subset of metals that were significantly associated with CHD in the primary multiple-metals model ($p - \text{trend} < 0.05$) underwent additional evaluation. First, we estimated associations between the metals and CHD using a multiple-metal model with each ln-transformed metal modeled using restricted cubic splines with knots at the 20th, 40th, 60th, and 80th percentiles of its distribution; the reference value ($\text{OR} = 1$) set at the 10th percentile ([@c19]); and the measured concentration replaced with the mean concentration $\pm 3\,\text{SD}$ for all observations with measured concentrations above this value. We also performed a sensitivity analysis of restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles.

Stratified analyses were performed by including metals in the multiple-metal model and corresponding dichotomous variables for baseline characteristics, including age ($< 65$, $\geq 65\,\text{years}$), sex, BMI ($< 25.0$, $\geq 25.0{\,{kg}/m}^{2}$), smoking status (never-smokers, ever-smokers), presence of hypertension, and diabetes (yes, no), as well as renal function (eGFR $< 90$, $\geq 90\;{mL}/\text{min}$ per $1.73{\, m}^{2}$). In addition, we evaluated the joint associations between metals that were significant in the multiple-metal model, and the individual metal was dichotomized as low ($Q1 + Q2$) and high ($Q3 + Q4$), and a four-category variable was created for two metals (i.e., low/low, high/low, low/high, and high/high) with low/low group as the reference. To determine whether the pairwise interactions were significantly different from expectations for multiplicative risks, we derived likelihood ratio test *p*-values, comparing the fit of models with jointly categorized exposures to corresponding models with lower-order terms for each metal only. Finally, we compared the baseline characteristics according to the quartiles of titanium using linear regression for continuous variables and chi-square tests for categorical variables. The purpose of this analysis was to explore the potential correlations between titanium and participants' characteristics because there was limited information about the sources of exposure to this metal, whereas it showed significant association with CHD (as described in the "Results" section). Analyses were conducted using SAS (version 9.3; SAS Institute Inc.) and R software (version 3.3.2; R Core Team), and a two-sided $p < 0.05$ was considered statistically significant.

Results {#s3}
=======

Characteristics of the Study Population {#s3.1}
---------------------------------------

In comparison with the controls, CHD cases were more likely to have hypertension, hyperlipidemia, and diabetes at baseline; they had slightly but significantly higher BMIs, higher pack-years among ever-smokers, and lower eGFRs; in addition, they were less likely to have never smoked or to have a high-school education ([Table 1](#t1){ref-type="table"}). No significant differences were found for alcohol intake status, physical activity levels, or family history of heart disease between the cases and controls. Concentrations of aluminum, titanium, manganese, copper, zinc, arsenic, strontium, barium, and lead were significantly higher in cases than controls, whereas selenium concentrations were significantly lower ([Table 2](#t2){ref-type="table"}). Among the 20 metals with less than 12% of samples below the LOD (see Table S1), most of them were significantly but modestly correlated with each other (Spearman's rank correlation coefficients $- 0.08 \sim 0.72$; see Table S2 and Figure S1).

###### 

Basic characteristics of study participants at baseline.

Table 1 lists variables in the first column; the corresponding values for controls (n equals 1621), cases (n equals 1621), and their p-values are listed in the other columns.

  Variables                                                             Controls ($n = 1,621$)   Cases ($n = 1,621$)   *p*-Value[^*a*^](#t1n1){ref-type="table-fn"}
  --------------------------------------------------------------------- ------------------------ --------------------- ----------------------------------------------
  Age (years)                                                           $65.6 \pm 7.4$           $65.7 \pm 7.3$        0.72
  Male sex, $n$ (%)                                                     789 (48.7)               789 (48.7)             
  BMI (${{kg}/m}^{2}$)                                                  $24.23 \pm 3.25$         $24.80 \pm 3.31$      $< 0.001$
  Smoking status, $n$ (%)                                                                                               
   Current smoker                                                       305 (18.8)               344 (21.2)             
   Former smoker                                                        179 (11.0)               203 (12.5)            0.06
   Never smoker                                                         1137 (70.1)              1074 (66.3)            
  Pack-years among ever-smokers[^*b*^](#t1n2){ref-type="table-fn"}      $29.1 \pm 20.3$          $31.8 \pm 22.6$       0.04
  Alcohol intake status, $n$ (%)                                                                                        
   Current drinker                                                      360 (22.2)               361 (22.3)             
   Former drinker                                                       78 (4.8)                 70 (4.3)              0.80
   Never drinker                                                        1183 (73.0)              1190 (73.4)            
  Education level, $n$ (%)                                                                                              
   Primary school or below                                              512 (31.6)               543 (33.5)             
   Middle school                                                        563 (34.7)               597 (36.8)            0.05
   High school or beyond                                                546 (33.7)               481 (29.7)             
  Physical activity (yes), $n$ (%)[^*c*^](#t1n3){ref-type="table-fn"}   1466 (90.4)              1437 (88.6)           0.10
  CHD family history, $n$ (%)                                           77 (4.8)                 78 (4.8)              0.93
  Hypertension, $n$ (%)[^*d*^](#t1n4){ref-type="table-fn"}              699 (43.1)               1074 (66.3)           $< 0.001$
  Hyperlipidemia, $n$ (%)[^*e*^](#t1n5){ref-type="table-fn"}            711 (43.9)               993 (61.3)            $< 0.001$
  Diabetes, $n$ (%)[^*f*^](#t1n6){ref-type="table-fn"}                  171 (10.5)               383 (23.6)            $< 0.001$
  eGFR (${mL}/\text{min}/1.73{\, m}^{2}$)                               $88.00 \pm 21.06$        $84.83 \pm 20.09$     $< 0.001$
  eGFR $\geq 90$, $n$ (%)                                               648 (40.0)               553 (34.1)            $< 0.001$
  Occupational categories                                                                                               
   Raw material production                                              210 (13.0)               229 (14.1)             
   Automobile parts manufacturing                                       662 (40.8)               700 (43.2)             
   Automobile assembly                                                  129 (8.0)                93 (5.7)              0.07
   Auxiliary service and management                                     32 (2.0)                 22 (1.4)               
   Others (e.g., affiliated schools)                                    564 (34.8)               558 (34.4)             
   Missing indicator                                                    24 (1.5)                 19 (1.2)               
  Diet categories ($\geq 5\,\text{times}/\text{week}$)                                                                  
   Meat                                                                 467 (28.8)               423 (26.1)            0.08
   Fish or seafood                                                      142 (8.8)                140 (8.6)             0.90
   Milk or dairy products                                               585 (36.1)               558 (34.4)            0.32
   Beans or soy foods                                                   420 (25.9)               402 (24.8)            0.47
   Fruits or vegetables                                                 1579 (97.4)              1562 (96.4)           0.09

Note: Normally distributed variables were presented as $\text{mean} \pm \text{SD}$. Non-normally distributed variables were presented as median (IQR). Categorical variables were presented as numbers (percentage). Data were complete for all variables except occupation. BMI, body mass index; eGFR, estimated glomerular filtration rate.

*p*-Values were derived from Student's *t*-tests or Mann-Whitney *U* tests for continuous variables according to the data distribution, and chi-square test for the category variables.

Numbers of packs smoked/$\text{day} \times \text{number}\,\text{of}\,\text{years}\,\text{smoked}$, among former and current smokers.

Physical activity was defined as exercise for at least 20 min per week for more than half a year.

Hypertension was defined as measured values $\geq 140\,\text{mmHg}$ for SBP or $\geq 90\,\text{mmHg}$ for DBP, self-reported physician diagnosis, or reported use of antihypertensive medication.

Hyperlipidemia was defined as total cholesterol $\geq 5.72\,\text{mmol}/L$, triglycerides $\geq 1.70\,\text{mmol}/L$, or a self-reported physician diagnosis, or antihyperlipidemia medication use.

Diabetes was defined as fasting glucose $\geq 7.0\,\text{mmol}/L$, self-reported physician diagnosis, or antidiabetic medication use (insulin or oral hypoglycemic agents).

###### 

Concentrations of plasma metals among study participants.

Table 2 lists variables in the first column; the corresponding values for controls (n equals 1621), cases (n equals 1621), and their p-values are listed in the other columns.

  Variables                   Controls ($n = 1,621$)       Cases ($n = 1,621$)          *p*-Value[^*a*^](#t2n1){ref-type="table-fn"}
  --------------------------- ---------------------------- ---------------------------- ----------------------------------------------
  Plasma metals ($\mu g/L$)                                                              
   Aluminum                   48.95 (31.00--97.29)         57.41 (33.14--144.75)        $< 0.001$
   Antimony                   0.14 (0.09--0.22)            0.14 (0.09--0.21)            0.37
   Arsenic                    1.96 (1.27--3.49)            2.32 (1.42--4.49)            $< 0.001$
   Barium                     35.47 (23.25--62.55)         40.53 (25.98--71.05)         $< 0.001$
   Cadmium                    0.30 (0.19--0.53)            0.27 (0.17--0.53)            0.06
   Chromium                   3.44 (2.67--4.58)            3.49 (2.64--4.54)            0.82
   Cobalt                     0.15 (0.12--0.20)            0.15 (0.12--0.20)            0.56
   Copper                     962.14 (856.05--1072.48)     970.93 (867.11--1097.38)     0.02
   Iron                       1183.21 (958.77--1483.43)    1202.71 (976.27--1471.85)    0.34
   Lead                       13.12 (8.84--20.71)          13.76 (9.52--23.05)          0.01
   Manganese                  4.05 (2.97--5.72)            4.21 (3.17--5.77)            0.03
   Molybdenum                 1.36 (1.09--1.74)            1.36 (1.10--1.78)            0.51
   Nickel                     3.03 (2.17--4.54)            3.07 (2.22--4.69)            0.27
   Rubidium                   357.09 (318.22--399.30)      354.91 (315.48--400.34)      0.31
   Selenium                   67.48 (57.67--78.69)         65.85 (56.88--76.87)         0.02
   Strontium                  35.91 (30.12--42.31)         36.67 (30.66--44.08)         0.003
   Thallium                   0.13 (0.10--0.18)            0.14 (0.10--0.19)            0.08
   Titanium                   29.14 (24.41--35.71)         30.32 (25.34--36.90)         $< 0.001$
   Vanadium                   0.67 (0.53--0.99)            0.68 (0.55--1.00)            0.33
   Zinc                       1193.53 (1014.72--2623.69)   1245.56 (1040.06--3012.34)   0.005

Note: Plasma tungsten, tin, and uranium concentrations were excluded from further analysis because of many samples $< \text{LOD}$ (98.3%, 80.2%, and 54.0%, respectively). Plasma cadmium, chromium, and iron were excluded from further analyses because of concerns about the use of plasma concentrations as a biomarker. Metal concentrations are presented as median (IQR).

*p*-Values were derived from Mann-Whitney *U* tests.

Metals Correlation Study {#s3.2}
------------------------

In comparison with controls in the main study, the 94 participants in the metals correlation study were younger (mean age 44 vs. 66 y), more likely to be male (56.4% vs. 48.7%) and to be current alcohol consumers (42.6% vs. 22.2%), and less likely to have diabetes (3.1% vs. 10.5%) (Table S3). Plasma levels of chromium, iron, and cadmium were not significantly correlated with concentrations in whole blood or in urine (Table S4), and previous studies have suggested that plasma concentrations may not be a reliable measure of internal exposure ([@c23]; [@c24]; [@c40]). Therefore, these metals were excluded from subsequent analyses.

Metals Exposure and Incident CHD {#s3.3}
--------------------------------

Five metals met our criterion ($p - \text{trend} < 0.05$ in the single-metal model) for further analysis: aluminum, arsenic, barium, selenium, and titanium (Table S5). Although the single-metal model *p*-trend for plasma rubidium was marginally significant ($p - \text{trend} < 0.05$), the FDR *p*-trend was 0.14, and it was therefore excluded from the multiple-metal models. None of the other metals evaluated in single-metal models had significant trend *p*-values.

In the multiple-metals model, trend tests remained significant, and adjusted ORs were similar to those from single-metal models for titanium ($\text{OR} = 1.32$; 95% CI: 1.03, 1.69 for the fourth vs. first quartile; $p - \text{trend} = 0.04$), arsenic ($\text{OR} = 1.78$; 95% CI: 1.29, 2.46; $p - \text{trend} = 0.001$), and selenium ($\text{OR} = 0.67$; 95% CI: 0.52, 0.85; $p - \text{trend} = 0.001$) ([Table 3](#t3){ref-type="table"}). In contrast, ORs for aluminum and barium were close to the null after adjustment for the other metals. The ORs did not change appreciably for any of the metals after additional adjustment of the multiple-metals model for occupation or consumption of major food groups (Table S6). Therefore, further analyses were limited to titanium, arsenic, and selenium, unless otherwise indicated.

###### 

Adjusted odds ratios \[95% confidence interval (CI)\] for incident CHD according to quartiles of exposure for plasma metals included in the multiple-metal model.

Table 3 lists plasma metals in the first column; the corresponding values of Q1, Q2, Q3, and Q4 (quartiles of plasma metals in micrograms per liter), and their p trends are listed in the other columns.

  Plasma metals                                             Quartiles of plasma metals ($\mu g/L$)[^*a*^](#t3n1){ref-type="table-fn"}   *p*-Trend[^*b*^](#t3n2){ref-type="table-fn"}                                           
  --------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------- ------------------- ------------------- -----------
  Aluminum ($\mu g/L$)[^*c*^](#t3n3){ref-type="table-fn"}   $< 31.03$                                                                   31.03--48.95                                   48.95--97.15        $> 97.15$            
   $n$ (case/control)                                       358/405                                                                     349/405                                        395/405             519/406              
   Model 1[^*d*^](#t3n4){ref-type="table-fn"}               1.00                                                                        0.93 (0.74, 1.16)                              1.05 (0.83, 1.32)   1.33 (1.07, 1.65)   0.001
   Model 2[^*e*^](#t3n5){ref-type="table-fn"}               1.00                                                                        0.85 (0.67, 1.08)                              0.90 (0.70, 1.15)   0.94 (0.71, 1.25)   0.83
  Arsenic ($\mu g/L$)                                       $< 1.28$                                                                    1.28--1.96                                     1.96--3.49          $> 3.49$             
   $n$ (case/control)                                       323/405                                                                     357/405                                        369/405             572/406              
   Model 1                                                  1.00                                                                        1.17 (0.93, 1.48)                              1.12 (0.89, 1.40)   1.68 (1.35, 2.09)   $< 0.001$
   Model 2                                                  1.00                                                                        1.17 (0.91, 1.50)                              1.15 (0.88, 1.50)   1.78 (1.29, 2.46)   0.001
  Barium ($\mu g/L$)[^*c*^](#t3n3){ref-type="table-fn"}     $< 23.26$                                                                   23.26--35.48                                   35.48--62.52        $> 62.52$            
   $n$ (case/control)                                       328/405                                                                     375/405                                        424/405             494/406              
   Model 1                                                  1.00                                                                        1.21 (0.96, 1.53)                              1.25 (1.00, 1.56)   1.44 (1.15, 1.79)   0.002
   Model 2                                                  1.00                                                                        1.15 (0.90, 1.47)                              1.03 (0.79, 1.34)   0.91 (0.66, 1.25)   0.41
  Selenium ($\mu g/L$)                                      $< 57.69$                                                                   57.69--67.48                                   67.48--78.66        $> 78.66$            
   $n$ (case/control)                                       438/405                                                                     437/405                                        392/406             354/405              
   Model 1                                                  1.00                                                                        0.97 (0.79, 1.19)                              0.88 (0.71, 1.10)   0.72 (0.57, 0.91)   0.007
   Model 2                                                  1.00                                                                        0.92 (0.74, 1.14)                              0.80 (0.64, 1.00)   0.67 (0.52, 0.85)   0.001
  Titanium ($\mu g/L$)                                      $< 24.42$                                                                   24.42--29.14                                   29.14--35.70        $> 35.70$            
   $n$ (case/control)                                       319/405                                                                     396/405                                        441/405             465/406              
   Model 1                                                  1.00                                                                        1.28 (1.02, 1.61)                              1.35 (1.07, 1.69)   1.37 (1.09, 1.73)   0.010
   Model 2                                                  1.00                                                                        1.28 (1.01, 1.62)                              1.33 (1.05, 1.69)   1.32 (1.03, 1.69)   0.04

Plasma metal concentration was presented as raw data.

*p*-Trend across quartiles of metals were obtained by including the median of each quartile (natural log-transformed) as a continuous variable in logistic regression models.

For aluminum, the inclusion of barium or arsenic in the model would attenuate the association to non-significant. For barium, the inclusion of arsenic or aluminum would attenuate the association to nonsignificant. Aluminum, arsenic and barium are significantly correlated with each other ($p < 0.01$), with high correlation coefficients \[aluminum--arsenic 0.58, aluminum--barium 0.62, arsenic--barium 0.71\].

Model 1: Metals were included in the conditional logistic regression models separately (single-metal model) and adjusted for BMI, smoking status, pack year, alcohol intake status, education, physical activity, hypertension, hyperlipidemia, family history of coronary heart disease, diabetes, and eGFR. The results for the rest metals in the single-metal model were shown in Table S5.

Model 2: Metals that were significant in the single-metal model ($p - \text{trend} < 0.05$) were included in the conditional logistic regression model simultaneously (multiple-metals model) and adjusted for the same variables as Model 1.

Spline regression analysis indicated significant linear associations for titanium and selenium ($p = 0.027$ and $p = 0.001$, respectively, with *p*-values for nonlinearity of 0.36 and 0.25) ([Figure 1](#f1){ref-type="fig"}). In contrast, the association between arsenic and CHD was nonlinear ($p\,\text{for}\,\text{nonlinearity} = 0.002$), with a sharp increase in slope for concentrations above $\sim 3.7\;\mu g/L$. Results were similar in the sensitivity analysis when different knots were applied (Figure S2).

![The restricted cubic spline for the association between plasma metals and incident CHD. The lines represent adjusted odds ratios based on restricted cubic splines for the log-transformed levels of plasma titanium, arsenic, and selenium in the multiple-metals conditional regression model. Knots were placed at the 20th, 40th, 60th, and 80th percentiles of the plasma metal distribution, and the reference value was set at the 10th percentile. Adjustment factors were BMI, smoking status, pack year, alcohol intake status, education, physical activity, hypertension, hyperlipidemia, family history of CHD, diabetes, and eGFR. The bars represent histograms of plasma metal distribution among the total population. The model included barium and aluminum as well. The numbers in parentheses show the plasma metal concentrations before log-transformation.](EHP1521_f1){#f1}

Subgroup Analyses and Metals Interaction Analyses {#s3.4}
-------------------------------------------------

There were no clear differences in associations between CHD and titanium, arsenic, or selenium according to strata of age, gender, BMI, smoking, hypertension, diabetes, and renal function (Table S7). The sample size in certain strata may be small to limit definite conclusion of effect modification by those variables (Table S7).

In the joint association analysis of two metals, although no significant *p*-interaction values were found, higher levels of titanium or arsenic were associated with increased risk of CHD when selenium level was low (equal to or below the median), and the association was attenuated to null when selenium level was high (above the median) ([Table 4](#t4){ref-type="table"}).

###### 

Adjusted odds ratios (95% CI) for incident CHD according to the combined categories of plasma metal levels.

Table 4 lists metals in the first column; the corresponding n values for cases or controls, odds ratios (95 percent confidence intervals), and their p interaction are listed in the other columns.

  Metals                                     $n$ (case/control)   Odds ratio (95% CI)[^*a*^](#t4n1){ref-type="table-fn"}   *p*-Interaction[^*b*^](#t4n2){ref-type="table-fn"}
  ------------------------------------------ -------------------- -------------------------------------------------------- ----------------------------------------------------
  Selenium-Arsenic                                                                                                          
   $\text{Low}\,{Se} + \text{Low}\,{As}$     369/426              1.00                                                     0.52
   $\text{Low}\,{Se} + \text{High}\,{As}$    506/384              1.37 (1.10, 1.69)                                        
   $\text{High}\,{Se} + \text{Low}\,{As}$    311/384              0.86 (0.68, 1.08)                                        
   $\text{High}\,{Se} + \text{High}\,{As}$   435/427              1.05 (0.85, 1.32)                                        
  Selenium-Titanium                                                                                                         
   $\text{Low}\,{Se} + \text{Low}\,{Ti}$     435/474              1.00                                                     0.29
   $\text{Low}\,{Se} + \text{High}\,{Ti}$    440/336              1.33 (1.07, 1.66)                                        
   $\text{High}\,{Se} + \text{Low}\,{Ti}$    280/336              0.87 (0.69, 1.11)                                        
   $\text{High}\,{Se} + \text{High}\,{Ti}$   466/475              0.98 (0.79, 1.22)                                        

Note: Metals that were significant in the multiple-metal model ($p < 0.05$) were included in the combined effect analysis. As, Arsenic; Se, Selenium; Ti, Titanium.

The multivariable-adjusted model included the combined categories of metals levels \[Low Se $\leq 67.48\;\mu g/L$ ($Q1 + Q2$), high Se $\geq 67.48\;\mu g/L$ ($Q3 + Q4$). Low As $\leq 1.96\;\mu g/L$ ($Q1 + Q2$), high As $\geq 1.96\;\mu g/L$ ($Q3 + Q4$). Low Ti $\leq 29.14\;\mu g/L$ ($Q1 + Q2$), high Ti $\geq 29.14\;\mu g/L$ ($Q3 + Q4$)\], BMI, smoking status, pack year, alcohol intake status, education, physical activity, hypertension, hyperlipidemia, family history of coronary heart disease, diabetes, and eGFR.

*p*-Interaction was the likelihood ratio test *p*-values comparing the fit of models with jointly categorized exposures to corresponding models with lower-order terms for each metal only.

Metals Variability Study {#s3.5}
------------------------

In general, the 138 participants in the metals variability study were similar to the control participants in the primary study, though they were slightly younger (mean age 62 vs. 66 y) and less likely to have diabetes (1.4% vs. 10.5%) at baseline (Table S8). When concentrations were compared in plasma samples collected 5 y apart, fair to good reproducibility was observed for titanium ($\text{ICC} = 0.56$, $r_{s} = 0.52$) and selenium ($\text{ICC} = 0.64$, $r_{s} = 0.73$); however, the reproducibility was poor for arsenic ($\text{ICC} = 0.25$, $r_{s} = 0.003$) (see Table S9). Of the other metals, reproducibility was fair to good (ICC 0.45--0.74) for plasma concentrations of barium, copper, lead, rubidium, and strontium, and poor for the remaining metals.

When comparing the baseline characteristics of the participants according to quartiles of titanium (Table S10), we found that, with increasing quartiles of plasma titanium, the proportions of women, never-smokers, and participants with hypertension and hyperlipidemia were higher ($p < 0.05$ for all).

Discussion {#s4}
==========

To the best of our knowledge, this study is the first and largest study to evaluate the prospective associations between internal exposures to multiple metals and incident CHD among Chinese adults. In our study population, plasma concentrations of titanium and arsenic were positively associated with incident CHD, whereas plasma selenium concentrations were inversely associated with incident CHD.

A meta-analysis of 18 studies calculated pooled relative risks of arsenic exposure by comparing the highest versus the lowest exposure category across studies ([@c18]). The pooled relative risks (95% CI) for CVD and CHD were 1.32 (95% CI: 1.05, 1.67) and 1.89 (95% CI: 1.33, 2.69), respectively ([@c18]). Yuan et al. ([@c46]) used group-level exposure from drinking water to explore the association with myocardial infarction mortality. Meanwhile, the HEALS cohort in the Bangladesh population used individual-level data on well water or urinary arsenic concentrations and reported a positive relation with all-cause ([@c2]) and cardiovascular mortality ([@c7]), and a nested case--control study within the HEALS cohort reported that well-water arsenic was associated with the incidence of fatal and nonfatal CVD ([@c43]). Furthermore, Moon et al. ([@c19]) found that urinary arsenic levels were positively associated with incident CHD ($n = 846$) in a cohort of 3,575 American Indians with low-moderate arsenic exposure (median urinary arsenic concentration was $9.7\;\mu g/g$ creatinine, in comparison with $199\;\mu g/g$ creatinine in the Bangladeshi population). A hospital based case--control study in Inner Mongolia examined the association of water and toenail arsenic with CVD ([@c36]). The median arsenic in drinking water sampled from each participant's home was $13.1\;\mu g/L$, and the adjusted OR for a $10\;\mu g/L$ increase in water arsenic was 1.19 (95% CI: 1.03, 1.38) ([@c36]). Positive associations also were reported for toenail arsenic ([@c36]). In accordance with a study of groundwater arsenic contamination across China ([@c30]), our study was conducted in a low-exposure area (below $10\;\mu g/L$ drinking water). We used plasma arsenic concentrations to estimate participants' exposure levels, rather than urine concentrations, but we also measured plasma and urine arsenic concentrations in a separate sample of 98 healthy adult residents of Shiyan, China. In this study sample, plasma and urine arsenic concentrations were moderately correlated ($\mathit{r}_{s} = 0.34$) with median concentrations of $3.32\;\mu g/L$ and $5.95\;\mu g/g$ creatinine ($3.67\;\mu g/L$), respectively. A study conducted among 100 healthy volunteers in France reported that the median concentration of plasma and urine arsenic was $6.2\;\mu g/L$ and $19\;\mu g/L$, respectively ([@c10]). The median concentration of plasma arsenic in a study (conducted 8 y later) of a similar French population ([@c6]) was close to the concentration found in our study (2.19 and $2.11\;\mu g/L$, respectively). Therefore, the plasma concentration of arsenic in our study (median concentration of controls $1.96\;\mu g/L$) was lower than the concentration in other studies. Our findings suggest a nonlinear association between plasma arsenic and incident CHD, with a significant positive association for the highest vs. lowest quartile of exposure ($> 3.49\;\mu g/L$ vs. $< 1.28\;\mu g/L$), whereas ORs were close to the null for the second and third quartiles, and showed a positive association with concentrations $> 3.7\;\mu g/L$, based on the spline regression model. Similar patterns were found in the HEALS study ([@c7]) and the Strong Heart Study ([@c19]). Further studies are needed to evaluate the threshold and reference dose of arsenic exposure and CVD risk. Our data provide evidence for a positive association between plasma arsenic and incident CHD in Chinese adults, even at relatively low to moderate exposure levels. The maximum arsenic concentration in our population was $23.95\;\mu g/L$, with the median values for cases and controls in the highest quartile of exposure 5.39 and $4.91\;\mu g/L$, respectively. The underlying biologic mechanisms may include increase of the reactive oxygen species production ([@c44]), may induce alterations in nitric oxide metabolism, and may affect endothelial function ([@c8]).

Fish and seafood intake is known to be important source of organic arsenic species ([@c22]; [@c34]); however, other nutrients in fish and seafood may have beneficial effects that reduce the risk of CVD ([@c20]). Therefore, fish and seafood consumption may confound associations between plasma arsenic and incident CVD. However, fish and seafood intake levels were low in the Shiyan study population (median of 1 serving/wk in both cases and controls), and thus the confounding could be minimal.

To the best of our knowledge, we are the first to report a significant positive association between plasma titanium and incident CHD. Titanium is the ninth most abundant element in the earth's crust and is widely used in many products, including paints, coatings, plastics, pharmaceuticals, food, cosmetics, and toothpaste ([@c32]). Furthermore, $\text{TiO}_{2}$ is commonly used as a component for articulating prosthetic implants ([@c32]). The median plasma titanium concentration among control participants in the present study was $29.14\mspace{9mu}\mu g/L$. Information about titanium levels in general populations is not available, but the mean serum titanium level in 32 U.S. patients 6 wk after repair of a femoral fracture with an intramedullary titanium implant was $49.38\;\mu g/L$ ([@c16]), and the mean serum titanium concentration measured in 30 U.S. adults 23--28 months after receiving titanium spinal implants was $2.6\;\mu g/L$, in comparison with $0.71\;\mu g/L$ in 13 samples from uncharacterized controls ([@c29]). These limited reports suggest that plasma titanium may be relatively high in our study population, but more information is needed to characterize titanium concentrations in representative populations of healthy individuals.

Although humans may be widely exposed to titanium in daily life, there is very little information on the potential health effects of chronic exposure to titanium. In our previous community-based cross-sectional study of 2,004 adult residents of Wuhan, China, who did not have a history of CVD or kidney diseases ([@c9]), urine titanium concentrations were associated with increased heart rate variability, an indicator of autonomic modulation of rhythmic heart rate. This finding suggests that titanium might affect cardiac autonomic balance. The median urine concentrations in this study were $33.1\;{mg}/g$ creatinine, which was similar to the median concentration of our correlation study population ($35.4\;\mu g/g$ creatinine). *In vitro* administration of $\text{TiO}_{2}$ nanoparticles to bronchial epithelial cells induced oxidative stress and production of a pro-inflammatory cytokine ([@c12]), which suggests that titanium might contribute to the etiology of CVD through pro-inflammatory effects.

Given the lack of information on titanium levels in general populations, we performed a post hoc analysis to identify participant characteristics associated with plasma titanium concentrations. The proportion of women, never-smokers, and participants with hypertension and hyperlipidemia increased from the lowest to highest quartile of plasma titanium (chi-square $p - \text{value} < 0.05$); however, the potential mechanism for the association remains to be explored. Our novel findings warrant confirmation in other populations and further investigation of potential mechanisms and sources of exposure.

Our analysis also identified significant inverse associations between incident CHD and selenium. Results from previous studies have been inconsistent, and a recent meta-analysis of 16 prospective studies suggested a significant benefit of CVD incidence and mortality within a narrow selenium range of $55–145\;\mu g/L$ ([@c49]). The NHANES III study in U.S. adults found no significant association between selenium (mean serum selenium concentration $125.6\;\mu g/L$) and CVD mortality overall, with a U-shaped dose--response curve, indicating an inverse association in the middle of the exposure distribution, and a positive association at the high end ([@c3]). The participants in a small Chinese cohort study (116 CVD deaths during follow-up of 1,103 cohort participants) reporting an inverse association with CHD mortality had a mean serum concentration of $73\;\mu g/L$ ([@c38]). However, a matched case--control study of 204 pairs of metabolic syndrome patients and controls in China reported a positive association between plasma selenium and the prevalence of metabolic syndrome and elevated fasting plasma glucose ([@c47]). The median plasma selenium concentration in the control group was $127.4\;\mu g/L$. Wilhelm et al. ([@c41]) reported a reference range for plasma or serum selenium of $50–120\mspace{9mu}\mu g/L$, according to a previous review performed by the Human Biomonitoring Commission ([@c11]). In our study, the median concentration was $64.3\;\mu g/L$ in the controls, and our results were consistent with studies in populations with lower baseline selenium concentrations ([@c49]). Our spline analysis suggested that the association continued to be negative at higher exposure levels. However, the estimates are no longer significant, which may due to sparse data for higher exposures, and it should be interpreted with great caution. Therefore, more studies are needed before firm conclusions can be made about the dose--response relationship between selenium and cardiovascular health.

With respect to the interaction between metals, we found exposure to high levels of selenium appeared to attenuate the positive associations between CVD and high-plasma titanium and arsenic. Selenium was reported to play a role in counteracting arsenic poisoning in *in vivo* and *in vitro* studies ([@c50]), and the antioxidant property of selenium may be involved ([@c50]). Xue et al. ([@c45]) studied biomarkers of oxidative stress and antioxidant activity in residents of a region in China where high-arsenic coal is used for home heating and cooking, including 138 residents (cases) with skin lesions associated with arsenic exposure (hyperkeratosis, depigmentation, and hyperpigmentation) and 76 controls without skin lesions. In comparison with cases that had high blood arsenic and low blood selenium ($\leq 0.1\;\mu g/{mL}$), cases with high arsenic and high selenium had lower levels of serum malondialdehyde (MDA, an indicator of lipid peroxidation); higher serum levels of the antioxidant enzymes glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase; lower urinary concentrations of 8-oxo-dG; and higher expression (mRNA and protein) of 8-oxoguanine DNA glucosylase 1 (a DNA repair enzyme) in peripheral blood mononuclear cells ([@c45]). Additional research is needed to confirm whether selenium may attenuate adverse associations of arsenic and titanium with CHD, and to investigate potential underlying mechanisms and the possibility of public health interventions.

For the present study, we systematically measured 23 metals in individual plasma specimens and applied multiple-metal models to examine the independent associations between metals and incident CHD. Furthermore, our case--control study was nested within a large prospective cohort, and the plasma metals were measured years before CHD onset. The incident CHD cases were confirmed by medical and death records and adjudicated by physicians. Medical record reviews and comprehensive clinical examinations were also performed to minimize the potential for undiagnosed or preclinical CHD cases among the controls. Additionally, we performed standardized quality controls in data collection and laboratory assays to reduce the potential of measurement error and systemic bias.

Nevertheless, this study also has potential limitations. First, we did not distinguish among different arsenic species or metabolites in plasma, and our results therefore represent associations averaged over both toxic inorganic arsenic and relatively nontoxic organic arsenic exposures primarily from fish and seafood intake. Second, as each metal has unique distributions in organs and in the circulation system, plasma metals may not be suitable biomarkers of internal exposure for all metals. For example, plasma metals are useful and valid to assess the exposure status for some metals (e.g., plasma selenium), whereas urine or whole blood concentrations are commonly used for others (e.g., urine arsenic and whole blood lead). However, we found significant correlations between plasma and blood concentrations for 13 of 20 metals examined in a separate correlation study, including arsenic and selenium; we also found significant concentrations between plasma and urine concentrations for 8 of the metals, including arsenic, selenium, and titanium. Nonetheless, plasma concentrations of some metals may be subject to potential contamination and should therefore be interpreted with caution (e.g., plasma lead contamination from hemolysis) ([@c33]). Third, although we could not explore the sources of metals, circulating metals can be viewed as internal biomarkers integrating all sources of exposure. Plasma metals were measured at only one timepoint and may not reflect usual or chronic exposures for metals with large fluctuations in plasma concentrations. Unfortunately, information regarding the biological half-lives of many metals is limited. However, concentrations of 11 of 17 plasma metals, including selenium and titanium (but not arsenic), were significantly correlated between samples from a separate population of 138 DFTJ cohort members that were collected 5 y apart. We selected age- and gender-matched controls from cohort members who were free of CVD at the end of the follow-up period, instead of using incidence density sampling to generate an estimate of the incidence rate ratio. Finally, estimating associations with multiple highly correlated metals is challenging ([@c4]), and future studies should explore the use of advanced statistical models to better account for the complexity of mixed exposures.

Conclusions {#s5}
===========

In conclusion, we observed significant associations between plasma concentrations of several metals and incident CHD in a Chinese population. Our findings require confirmation but may have important implications for public health, given the high burden of CVD, both in China and worldwide, and the possibility that low-to-moderate exposures to metals may be widespread.
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=====================
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Click here for additional data file.
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